Amylyx Pharmaceuticals, Inc.

AMLXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1658551

Concept	FY2025	FY2024	FY2023	FY2022
Revenue from Contract with Customer, Excluding Assessed Tax	$87.4M	$380.8M	$22.2M	$22.2M
Cost of Goods and Services Sold	$6.0M	$25.4M	$3.0M	$3.0M
Research and Development Expense	$104.1M	$128.2M	$44.0M	$44.0M
Selling, General and Administrative Expense	$114.3M	$188.4M	$38.9M	$38.9M
Operating Income (Loss)	-$314.7M	$38.8M	-$82.7M	-$82.7M
Nonoperating Income (Expense)	$12.6M	$15.5M	-$5.2M	-$5.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$302.1M	$54.3M	-$87.9M	-$87.9M
Income Tax Expense (Benefit)	-$393.0K	$5.0M	$774.0K

Concept	FY2025	FY2024	FY2023	FY2022
Assets	$193.6M	$517.5M	$391.5M	$105.6M
Assets, Current	$189.4M	$464.7M	$382.1M	$105.0M
Cash and Cash Equivalents, at Carrying Value	$77.4M	$170.2M	$62.5M	$50.2M
Accounts Receivable, after Allowance for Credit Loss, Current	$447.0K	$40.0M	$15.3M	$15.3M
Inventory, Net	—	$38.3M	$9.8M	$9.8M
Liabilities	$28.9M	$84.0M	$50.8M	$17.4M
Liabilities, Current	$28.4M	$82.0M	$46.6M	$17.4M
Accounts Payable, Current	$2.9M	$22.1M	$6.3M	$4.4M
Stockholders' Equity Attributable to Parent

Concept	FY2025	FY2024	FY2023	FY2022
Net Cash Provided by (Used in) Operating Activities	-$167.6M	$11.9M	-$74.8M	-$74.8M
Net Cash Provided by (Used in) Investing Activities	$75.7M	$92.1M	-$46.4M	-$46.4M
Net Cash Provided by (Used in) Financing Activities	$348.0K	$3.5M	$158.5M	$158.5M
Payments to Acquire Property, Plant, and Equipment	$157.0K	$1.2M	$353.0K	$353.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)